---
title: "Fosun Pharma Shenzhen wins China approval to start Phase I trial of FXR0906 for hypertriglyceridemia"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292748567.md"
description: "Fosun Pharma (Shenzhen) received Chinese regulatory approval to initiate Phase I clinical trials for FXR0906, a liver-targeted siRNA therapy designed to lower serum triglycerides in patients with hypertriglyceridemia. Shanghai Fosun Pharmaceutical holds exclusive rights for the drug's development and commercialization in China, Hong Kong, and Macau. As of July 2026, no siRNA drugs for this indication have been approved in China."
datetime: "2026-07-15T10:14:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292748567.md)
  - [en](https://longbridge.com/en/news/292748567.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292748567.md)
generator: "portal-rs"
---

# Fosun Pharma Shenzhen wins China approval to start Phase I trial of FXR0906 for hypertriglyceridemia

-   Fosun Pharma (Shenzhen) won Chinese regulator clearance to start Phase I trials of FXR0906 for hypertriglyceridemia. \* FXR0906 is a liver-targeted siRNA designed to silence APOC3 mRNA, aiming to lower patients’ serum triglycerides. \* Shanghai Fosun Pharmaceutical holds exclusive China, Hong Kong, Macau rights to develop, manufacture, register, commercialize FXR0906. \* R&D spending on FXR0906 reached about RMB 71 million as of June 2026, including license fees. \* No siRNA drug for hypertriglyceridemia has been cleared for marketing in China as of July 15, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12245295), on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [02196.HK](https://longbridge.com/en/quote/02196.HK.md)
- [600196.CN](https://longbridge.com/en/quote/600196.CN.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Fosun Pharma unit starts China Phase II trial of COPD drug candidate FXS7553](https://longbridge.com/en/news/295775012.md)
- [Fosun Pharma Sets March 2026 Board Meeting to Approve 2025 Results and Dividend Plan](https://longbridge.com/en/news/278366476.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [SiranBio raises nearly CNY 400 million in Pre-A, A and A+ rounds, Suzhou Angel Guidance Fund says](https://longbridge.com/en/news/296444537.md)
- [CStone says China NMPA clears IND for CS5007 EGFR/HER3 bispecific ADC](https://longbridge.com/en/news/296540686.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**